NYSE:RCUS Arcus Biosciences Q2 2025 Earnings Report $26.08 +0.04 (+0.13%) Closing price 05/5/2026 03:59 PM EasternExtended Trading$24.18 -1.91 (-7.30%) As of 05/5/2026 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Arcus Biosciences EPS ResultsActual EPS-$1.11Consensus EPS -$1.14Beat/MissBeat by +$0.03One Year Ago EPS-$1.02Arcus Biosciences Revenue ResultsActual Revenue$160.00 millionExpected Revenue$32.86 millionBeat/MissBeat by +$127.14 millionYoY Revenue Growth+310.30%Arcus Biosciences Announcement DetailsQuarterQ2 2025Date8/6/2025TimeAfter Market ClosesConference Call DateWednesday, August 6, 2025Conference Call Time4:05PM ETConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Arcus Biosciences Earnings HeadlinesArcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript1 hour ago | seekingalpha.comArcus (RCUS) Q1 2026 Earnings Call TranscriptMay 5 at 7:33 PM | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline UpdateMay 5 at 4:05 PM | businesswire.comArcus Biosciences Inc (RCUS) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 5 at 9:31 AM | finance.yahoo.comArcus Advances Quemliclustat With Completed Phase 1 Metabolism StudyMay 2, 2026 | tipranks.comSee More Arcus Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcus Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcus Biosciences and other key companies, straight to your email. Email Address About Arcus BiosciencesArcus Biosciences (NYSE:RCUS) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells. The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody. Additional pipeline assets explore dual checkpoint blockade and next-generation immune modulators. Arcus conducts multi-center clinical trials across North America, Europe and Asia, collaborating with academic institutions and global partners to advance its oncology portfolio. Founded in 2015 and headquartered in Redwood City, California, Arcus completed its initial public offering on the New York Stock Exchange in June 2020 under the ticker RCUS. The company has since forged strategic alliances with leading biopharmaceutical firms to accelerate clinical development and broaden the potential application of its immuno-oncology therapeutics. Arcus is led by President and Chief Executive Officer Terry Rosen, who co-founded the company and brings extensive experience in biotech leadership and oncology drug development. The senior management team combines expertise in translational medicine, clinical operations and commercial strategy to guide Arcus toward its goal of delivering new treatment options for patients with cancer.View Arcus Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
